| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/16/2002 | US20020058309 Nucleotide sequences for use in the treatment of nervous system disorders and neuronal damage |
| 05/16/2002 | US20020058307 Nucleotide sequences coding preferential polypeptides; for use in diagnosis and treatment of infection, cancer, autoimmune diseases, allergies, blood disorders, crohn's disease, sepsis and psoriasis |
| 05/16/2002 | US20020058284 Methods and compositions for treating macrophage-mediated diseases |
| 05/16/2002 | US20020058275 Adjustment of defective fitting nucleotide sequences; obtain nucleotide sequence samples, incubate dimer binding protein, monitor sample for bound complexes |
| 05/16/2002 | US20020058267 Nucleotide sequences coding polypeptide for use in the treatment of alzheimer's disease |
| 05/16/2002 | US20020058264 Human regulatory molecules |
| 05/16/2002 | US20020058259 Regulation of human lipoxin A4 receptor-like protein |
| 05/16/2002 | US20020058241 Antibody for use in the treatment of prostate cancer |
| 05/16/2002 | US20020058071 Dietary supplement comprising aloe vera, collagen, a chromium mixture such as chromium polynicotinate, linoleic acid (especially conjugated) and natural amino acids. |
| 05/16/2002 | US20020058069 Use of microparticles having a protein and an antibody adsorbed thereon for preparing a pharmaceutical composition for intranasal administration |
| 05/16/2002 | US20020058067 Solid drug delivery system |
| 05/16/2002 | US20020058041 Kidney-specific tumor vaccine directed against kidney tumor antigen G-250 |
| 05/16/2002 | US20020058040 Injectable vaccine composition comprising an immunogenic conjugate in a water in oil emulsion; enhanced immunogenicity after storage at about -18 degrees C. |
| 05/16/2002 | US20020058038 Specific octapeptides, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds and immune effector cells raised in response to presentation of these epitopes. |
| 05/16/2002 | US20020058037 Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease |
| 05/16/2002 | US20020058036 Novel fibroblast growth factor and nucleic acids encoding same |
| 05/16/2002 | US20020058035 Reducing FSH levels by administering a GnRH antagonist to reduce both plasma FSH and LH levels; treating prostatic intraepithelial neoplasia, pedophilia, infertility, vaginal bleeding; in vitro fertilization and male contraception |
| 05/16/2002 | US20020058034 Treating or ameliorating an autoimmune condition, an allergic reaction or asthma |
| 05/16/2002 | US20020058029 Anti-CD40L, anti-B7.1 (CD80), anti-B7.2(CD86), CD40 antibody or anti-CD4 antibody; both may be administered separately or in combination, and in any order. |
| 05/16/2002 | US20020058027 C1 bacteriophage lytic system |
| 05/16/2002 | US20020058026 HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10 |
| 05/16/2002 | US20020058024 Modulators of the function of receptors of the TNF/NGF receptor family and other proteins |
| 05/16/2002 | US20020058022 Novel compounds |
| 05/16/2002 | US20020058020 Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins |
| 05/16/2002 | US20020058018 Isolated from a cDNA library of fetal liver-spleen tissue |
| 05/16/2002 | DE10056136A1 Inhibiting leukocyte or tumor cell adhesion to vascular endothelial cells e.g. for combating inflammation or metastasis, using e.g. pregnancy proteins or selectin binding liposomes containing calcium-binding compound |
| 05/16/2002 | DE10054687A1 Inhibitoren von Transglutaminasen Inhibitors of transglutaminases |
| 05/16/2002 | DE10054303A1 Analoga, Agonisten, Antagonisten und Varianten der Oxidoreduktase-Enzymaktivität des Makrophagen-Migrations-Inhibitions-Faktors (MIF) als Immunmodulatoren, Therapeutika, Diagnostika und Screening-Agenzien bei inflammatorischen und Immunerkrankungen Analogues, agonists, antagonists, and variants of the oxidoreductase enzyme activity of macrophage migration inhibitory factor (MIF) as immunomodulators, therapeutic agents, diagnostic and screening agents in inflammatory and immune diseases |
| 05/16/2002 | DE10054279A1 Verwendung von Liganden von Todesrezeptoren oder RIP zur Auslösung des Caspase-unabhängigen Zelltods und Verbindungen zur Inhibition des Caspase-unabhängigen Zelltods Use of ligands of death receptors or RIP to trigger the caspase-independent cell death and compounds for inhibition of the caspase-independent cell death |
| 05/16/2002 | CA2437942A1 Chimeric molecules to modulate gene expression |
| 05/16/2002 | CA2429018A1 Method for treating hemophilia b |
| 05/16/2002 | CA2428453A1 C. elegans genes involved in viability and/or reproduction and uses thereof |
| 05/16/2002 | CA2428241A1 Novel human potassium channel beta subunit |
| 05/16/2002 | CA2428176A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 05/16/2002 | CA2428159A1 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 05/16/2002 | CA2428141A1 Use of selectin-binding pregnancy proteins, liposomes, native mucin fragments and mimetic compounds for the treatment and prophylaxis of inflammatory diseases, for preventing metastatic spread and for the prophylaxis of tumour diseases |
| 05/16/2002 | CA2428114A1 Apolipoprotein analogues |
| 05/16/2002 | CA2428055A1 Process for the preparation of latent antithrombin iii |
| 05/16/2002 | CA2427622A1 Methods for detecting the efficacy of anticancer treatments |
| 05/16/2002 | CA2426730A1 Calcilytic compounds |
| 05/16/2002 | CA2426508A1 Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states |
| 05/16/2002 | CA2426037A1 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | CA2426030A1 Methods of treating disorders related to apoe |
| 05/16/2002 | CA2425980A1 Foggy |
| 05/16/2002 | CA2425829A1 Proteases |
| 05/15/2002 | EP1205552A1 Virulence of streptococci, involving ORFs from Streptococcus suis |
| 05/15/2002 | EP1205551A1 Growth hormone and growth hormone releasing hormone compositions |
| 05/15/2002 | EP1205550A1 Polypeptides and nucleic acids encoding the same |
| 05/15/2002 | EP1205549A1 Gene expressed specifically in human fetal heart muscle |
| 05/15/2002 | EP1205547A2 DNA mutagenesis by random fragmentation and reassembly |
| 05/15/2002 | EP1205489A1 Polypeptide and nucleic acids encoding the same |
| 05/15/2002 | EP1205191A1 Targeted modification of intracellular compounds |
| 05/15/2002 | EP1205189A2 Combination of a prostaglandin agonist and a HMG-CoA reductase inhibitor for the stimulation of bone growth |
| 05/15/2002 | EP1205186A1 Compositions for promoting passive elongation of vesical smooth muscle |
| 05/15/2002 | EP1205185A1 Uterine contraction inhibitors |
| 05/15/2002 | EP1205184A1 Methylsilanol hydroxyproline aspartate-based composition |
| 05/15/2002 | EP1204870A2 Method for determining physiological effects of hemoglobin |
| 05/15/2002 | EP1204868A1 Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| 05/15/2002 | EP1204760A2 Polynucleotides regulating the activation of the expression of a gene in the heart and its uses in gene therapy |
| 05/15/2002 | EP1204757A1 Neutral cerebral-sphingomyelinase |
| 05/15/2002 | EP1204756A2 Method of determining the activity of 1-deoxy-d-xylulose-5-phosphate reductoisomerase and 1-deoxy-d-xylulose-5-phosphate synthase |
| 05/15/2002 | EP1204754A2 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby |
| 05/15/2002 | EP1204748A2 New g-protein coupled receptor and dna sequences thereof |
| 05/15/2002 | EP1204747A1 G protein-coupled receptor expressed in brain |
| 05/15/2002 | EP1204745A2 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
| 05/15/2002 | EP1204744A1 Isolated peptide of the horny layer and use thereof |
| 05/15/2002 | EP1204742A2 Oligonucleotides for inhibiting the expression of human eg5 |
| 05/15/2002 | EP1204682A2 Compositions and methods for the treatment of tumors |
| 05/15/2002 | EP1204681A2 Helical cytokine zalpha48 |
| 05/15/2002 | EP1204679A1 Peptides containing n-substituted d-amino acids for preventing beta-strand association |
| 05/15/2002 | EP1204677A2 Cyclohexapeptide compounds, process for their production and their use as a pharmaceutical |
| 05/15/2002 | EP1204676A1 Streptogramin derivatives, preparation and compositions containing same |
| 05/15/2002 | EP1204675A1 Streptogramin derivatives, production thereof and compositions containing the same |
| 05/15/2002 | EP1204674A2 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 05/15/2002 | EP1204672A1 High affinity vascular endothelial growth factor (vegf) receptor nucleic acid ligands and inhibitors |
| 05/15/2002 | EP1204657A1 Piperidine and pyrrolidine derivatives displaying neuronal activity |
| 05/15/2002 | EP1204656A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride |
| 05/15/2002 | EP1204655A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 05/15/2002 | EP1204430A2 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 05/15/2002 | EP1204429A2 Sustained release formulation of a peptide |
| 05/15/2002 | EP1204427A1 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
| 05/15/2002 | EP1204423A1 Therapeutic antibody against muc-1 antigen and methods for their use |
| 05/15/2002 | EP1204419A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 05/15/2002 | EP1204411A1 Apicidin-derived cyclic tetrapeptides |
| 05/15/2002 | EP1204409A1 Microparticles for pulmonary administration |
| 05/15/2002 | EP1204407A2 Implantable active ingredient depot |
| 05/15/2002 | EP1204332A1 Aspartic and malic acid inhibition of beta-glucuronidase |
| 05/15/2002 | EP1204321A2 Super-active porcine growth hormone releasing hormone analog |
| 05/15/2002 | EP1054686B1 Pharmaceutical formulation of a didemnin compound |
| 05/15/2002 | EP0854700B1 Use of bradykinin antagonists for stimulating or inducing hair growth and/or arresting hair loss |
| 05/15/2002 | EP0750509B1 USE OF IL-12 AND IL-12 ANTAGONISTS for the manufacture of a pharmaceutical composition for THE TREATMENT OF AUTOIMMUNE DISEASES |
| 05/15/2002 | EP0729460B1 Substituted 5-ring heterocycles, their preparation and their use |
| 05/15/2002 | EP0610499B1 Proteoglycan(g 009) effective in enhancing antitumor immunity |
| 05/15/2002 | CN1349543A Membrane disruptive peptides covalently oligomerized |
| 05/15/2002 | CN1349542A Heterocyclic compounds, intermediates thereof and elastase inhibitors |
| 05/15/2002 | CN1349526A Prodrugs of thrombin inhibitors |
| 05/15/2002 | CN1349496A Caspase inhibitors and the use thereof |
| 05/15/2002 | CN1349411A Compositions containing benzimidazolones and progestogens |
| 05/15/2002 | CN1349410A Use of heparin-binding antagonists in the inhibition of bradykinin release |
| 05/15/2002 | CN1349409A Metabolic intervention with GLP-1 to improve the function of ischemic anc reperfused tissue |